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Looking to nature for a new 
concept in antimicrobial 
treatments: isoflavonoids from 
Cytisus striatus as antibiotic 
adjuvants against MRSA
Ana Cristina Abreu1,2, Aline Coqueiro1, Andi R. Sultan3, Nicole Lemmens3, Hye Kyong Kim1, 
Robert Verpoorte1, Willem J. B. van Wamel3, Manuel Simões2 & Young Hae Choi1
The spread of multidrug-resistant Staphylococcus aureus strains, including methicillin-resistant S. 
aureus (MRSA), has shortened the useful life of anti-staphylococcal drugs enormously. Two approaches 
can be followed to address this problem: screening various sources for new leads for antibiotics or 
finding ways to disable the resistance mechanisms to existing antibiotics. Plants are resistant to most 
microorganisms, but despite extensive efforts to identify metabolites that are responsible for this 
resistance, no substantial progress has been made. Plants possibly use multiple strategies to deal with 
microorganisms that evolved over time. For this reason, we searched for plants that could potentiate 
the effects of known antibiotics. From 29 plant species tested, Cytisus striatus clearly showed such 
an activity and an NMR-based metabolomics study allowed the identification of compounds from the 
plant extracts that could act as antibiotic adjuvants. Isoflavonoids were found to potentiate the effect 
of ciprofloxacin and erythromycin against MRSA strains. For the structure-activity relationship (SAR), 
22 isoflavonoids were assessed as antibiotic adjuvants. This study reveals a clear synergy between 
isoflavonoids and the tested antibiotics, showing their great potential for applications in the clinical 
therapy of infections with antibiotic-resistant microorganisms such as MRSA.
The worldwide spread of multidrug-resistant (MDR) bacteria is increasingly attracting the attention of global 
surveillance authorities and media, and is undoubtedly rated as a major health threat in the 21st century. Each 
year over 13 million deaths in the world are attributed to the emergence of new infectious diseases or to the 
re-emergence of old pathogens with new resistance determinants1. This situation affects everyone, independently 
of age, gender or the country in which they live, and threatens to undermine all recent notable achievements of 
modern medicine. The fact that only 50 years of use of antibiotics has already led to widespread resistance shows 
that more sophisticated systems are required to effectively treat infectious diseases.
Natural products of microbial origin have mainly, though not exclusively, been the most important sources 
of leading antimicrobials for the pharmaceutical industry2, 3. Although plants have been studied intensively in 
the hope of finding novel antibiotics, none of them have lived up to expectations so far. Plants have different 
levels of defense against microorganisms, including fungi, yeasts and bacteria4 – constitutive chemical defense, 
direct inducible chemical defense (e.g. phytoanticipins) and gene-level inducible chemical defense (e.g. phy-
toalexins) – thereby producing an array of structurally diverse secondary metabolites. In most cases, studies 
have led to the isolation of single compounds that were generally not very active in in vitro tests5, whereas the 
synergistic interactions between various metabolites could enhance the activity of these otherwise weak anti-
microbial agents. Indeed, when isolated, these antimicrobial metabolites exhibit only weak or moderate activity 
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with minimal inhibitory concentrations (MICs) typically in the range of 100–1000 µg/mL, that is, several orders 
of magnitude above those of typical antibiotics produced by bacteria and fungi (MICs, 0.01–10 µg/mL)5, account-
ing for the absence of plant-derived antimicrobials in clinical applications6. A likely explanation for this is that 
plants, rather than relying on single metabolites, use a combination of strategies and a highly efficient defense 
system that includes very diverse molecules ranging from proteins to H2O2 and oxygen radicals, which most likely 
complement each other, to deal with microbial threats. The defense strategies may thus involve the synergistic 
activity of two or more compounds, which could act via different mechanisms and/or targets7. A great number 
of plant metabolites have been reported to exhibit these mechanisms involving the inhibition of several MDR 
efflux pumps for Gram-positive bacteria4, 8–15 implicated in bacterial resistance to several antibiotic classes, or 
to inhibit protein-binding proteins including (PBP)-2a8, 16, 17, among others. It is important to bear in mind that 
millions of years of evolution have resulted in plant defense systems that have proved to be not readily susceptible 
to microbial resistance mechanisms. It is this capability that triggers the interest in further studies, as there could 
be a lesson to learn from such an evolutionary successful strategy.
The goal of this study, thus, is to test whether it is possible to take advantage of a plant’s powerful defense sys-
tem, presumably based on complex synergistic interactions, to potentiate the activity of known antibiotics. Such 
a complex biological question is perfectly suited to a systems biology approach since a reductionist approach 
such as the conventional bioassay-guided fractionation cannot reveal interactions between compounds, such 
as synergy. Indeed, the full understanding of synergy in the biological activities of natural products is a major 
challenge18, 19. In contrast to the classical approach, in which while individually active, albeit weak, antimicrobial 
compounds may be identified, detecting synergistic interactions would imply many compounds being isolated in 
sufficient amounts to test them in an almost infinite number of combinations. A metabolomics approach seemed 
to be more promising. Metabolomics combines the use of a powerful analytical platform for data collection with 
multivariate data analysis of the collected information. Thus, the metabolites that may be correlated with the 
synergistic activities are revealed and can then be identified.
Cytisus striatus (Fabaceae), commonly known as Portuguese broom, a very abundant shrub in the Iberian 
Peninsula, was selected from among several other plants20 for its strong potentiating activity of ciprofloxa-
cin and erythromycin against one of the most menacing bacterial strains, MRSA, which causes serious, inva-
sive and life-threatening infections worldwide21. MRSA strains belonging to CC8, including the common 
ST239 found in Asia and a Dutch ST8-MRSA, were tested. The starting point for the study was to evaluate the 
antibiotic-potentiating activity of different types of extracts of this plant with proven antimicrobial activity. All 
extracts were submitted to 1H-NMR-based metabolomics. Supervised multivariate data analysis was then applied 
to identify the signals related to the high potentiating activity. The next step was to isolate the compounds respon-
sible for these signals by NMR-based metabolomics guided fractionation, identify them and test various combi-
nations for a synergistic antimicrobial potentiating activity on MRSA strains.
Fabaceae plants have been studied extensively for their phytoalexins, antimicrobial isoflavonoids that are 
produced after infection22. Isoflavonoids themselves are well known for their therapeutic properties, as they 
have anti-inflammatory, estrogenic, anti-estrogenic, anticancer, antibiotic and radical scavenging activities23–26. 
Their antimicrobial activity has been reported to be low or moderate in most cases18, 27, 28, but they are seemingly 
involved in the inducible defense response of plants in this family. However, their mechanism of action remains 
largely unexplained. Similarly, the potentiating activity on ciprofloxacin against S. aureus19, 29–31, described for 
some isoflavonoids, is not yet understood. The study showed that isoflavonoids were involved in the potentiating 
effect in C. striatus. Based on these results, a further 22 isoflavonoids from different sources were evaluated for 
their antibacterial and synergistic effects in combination with ciprofloxacin and erythromycin against S. aureus 
strains.
Results
Antibacterial and antibiotic synergistic activities of C. striatus leaf, flower and twig metha-
nolic extracts. Seven S. aureus strains were included in the experiments. Testing different bacterial strains 
should show whether the mode of action of the plant extract and its interaction with the antibiotic depends 
on the resistance profile of the strains. The characterization of the strains is described in Table 1. Two ST239-
type MRSA strains harboring staphylococcal cassette chromosome mec (SCCmec) were chosen: RWW337 (from 
Malaysia) and M116 (from Indonesia). ST239-type MRSA strains are probably the most predominant clone of 
MRSA causing hospital-acquired infections33. ST8 CA-MRSA with SCCmecIV (USA300) has been predomi-
nant, causing infections outside the health-care environment in the United States34. In this study, we investigated 
one Dutch ST8-MRSA (RWW50) carrying the SCCmec element. One ST20 clinical S. aureus strain (M82), also 
from Indonesia, was included as well. The Laboratory strains S. aureus RN6390 (a natural respiratory epithelial 
cell line that is a sigB-deficient mutant) and CECT 976 (from the Spanish collection), already used as a model 
microorganism for antimicrobial tests with phytochemical compounds35, 36, were included in the experiments. 
S. aureus SA1199B, derived from a methicillin-susceptible S. aureus (MSSA) bloodstream isolate from a patient 
with endocarditis, was used as a control strain since it overexpresses the NorA MDR efflux pump. The MICs of 
ciprofloxacin and erythromycin were determined for each strain by microdilution techniques according to the 
Clinical and Laboratory Standards Institute (CLSI) guidelines32 and also showed in Table 1. The MIC of the ethyl 
acetate fractions of the methanolic extracts of C. striatus leaves, flowers and twigs were also determined against 
the seven S. aureus strains. None of the extracts exhibited a MIC below 1 mg/mL against the S. aureus strains 
(Supplementary Table 1).
The methanolic extracts of leaves, flowers and twigs of C. striatus (EtOAc fractions with a concentration of 
0.5 mg/mL) were assessed for their potentiating effect of ciprofloxacin and erythromycin activity against the seven 
S. aureus strains, using the disk diffusion method (Table 2). The different parts of the plant showed different 
antibiotic-potentiating activities. The leaf extract showed the best potentiating effect on both ciprofloxacin and 
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erythromycin against several strains. Potentiation was also obtained when combinations were tested with the 
checkerboard assay (Supplementary Table 1). The flower extract showed additive and potentiating effects on 
the antibiotics only against S. aureus strains CECT 976 and SA1199B, respectively. The twig extract showed no 
antibiotic-potentiating activity against the tested seven S. aureus strains. The inhibition zone diameter (IZD) of 
each combination was never lower than that produced by each antibiotic alone (P > 0.05), proving that there was 
no antagonism detected in the combinations.
1H-NMR measurement of the extracts of different parts of C. striatus. 1H-NMR was applied to 
obtain metabolic profiles of all samples37. Visual inspection of the 1H-NMR spectra of the EtOAc fractions of leaf, 
flower and twig extracts revealed some differences in their chemical profiles (Supplementary Fig. 1), especially in 
the phenolic region, which could be responsible for differences in the antibiotic-potentiating activity: leaves (most 
active) > flower > twig (nonactive). Different extracts were prepared to enable the use of multivariate data analy-
sis to identify the markers of activity (Supplementary Fig. 2). A high chemical variation is essential to significantly 
correlate activity and chemical data. Therefore, leaves or flowers (active parts) were mixed with twigs (nonactive 
parts) in various ratios in order to obtain this variation. These mixtures were extracted using different solvents, 
temperature and pressure conditions (Supplementary Table 2). The resulting 54 extracts (EtOAc fractions) were 
assayed for their potentiation of the activity of ciprofloxacin and erythromycin against S. aureus CECT 976 using 
the disk diffusion method (Fig. 1). In general, extracts obtained with 100% methanol showed a higher potentiat-
ing activity than those prepared with 75- and 50% MeOH in water (P < 0.05); temperature and pressure did not 
significantly affect the activity (P < 0.05).
The 1H-NMR data obtained for the 54 samples were correlated with potentiating activity data by orthogonal 
partial least squares (OPLS) modeling to investigate the grouping of the samples according to the potentiat-
ing activity of ciprofloxacin (Fig. 2a) and erythromycin (Fig. 2b). The aromatic region (δ 6.0–8.6) was consid-
ered since phenolic compounds were expected to have a higher therapeutic potential. Both OPLS score plots of 
S. aureus CIP ERY Origin Relevant characteristics
CECT 976 1.0 (S) 0.25 (S) Laboratory strain
From Spanish Type Culture 
Collection; equivalent to ATCC 
13565; no antibiotic resistance
RN6390 0.25 (S) 0.5 (S) Laboratory strain ST8; no antibiotic resistance
SA1199B 4 (R) n.p. Laboratory strain
NorA-overproducing derivative 
of a clinical isolate, SA-1199, also 
has A116E GrlA substitution, 
MSSA
M82 0.25 (S) 0.5 (S) Indonesia (CI) ST20-MSSA
M116 32 (R) 32 (R) Indonesia (CI) ST239-MRSA
RWW337 16 (R) >10 000 (R) Malaysia (CI) ST239-MRSA
RWW50 2 (I) 64 (R)
Laboratory strain 
(collection MMIZ 
Erasmus MC)
ST8-MRSA
Table 1. Characterization of Staphylococcus aureus strains. Minimal inhibitory concentrations (MICs) of 
ciprofloxacin (CIP) and erythromycin (ERY) were determined for each strain (µg/mL) according to CLSI 
guidelines32, which were classified as resistant (R), intermediate (I) or susceptible (S) to each antibiotic. Origin 
and genetic profiles of the strains are described. n.p. not performed. CI – clinical isolate.
Increased IZD (IZDc – IZDa) (mm)
S. aureus 
strains
Leaf Flower Twig
CIP ERY CIP ERY CIP ERY
CECT 976 6.3 ± 1.0 (P) 9.1 ± 0.6 (P) 5.4 ± 1.2 (A) 4.5 ± 1.0 (A) — —
M116 7.0 ± 1.0 (P) 10.0 ± 0.0 (P) — — — —
RWW337 8.3 ± 0.6 (P) — — — — —
RWW50 7.0 ± 0.0 (P) 5.0 ± 1.0 (A) — — — —
M82 4.0 ± 0.0 (A) 4.5 ± 0.0 (A) — — — —
RN6390 — 5.0 ± 0.3 (A) — — — —
SA1199B 14.0 ± 2.5 (P) n.p. 17.3 ± 0.3 (P) n.p. — n.p.
Table 2. Antibiotic-potentiating activity of Cytisus striatus extracts on different Staphylococcus aureus strains. 
The activity is expressed as the increase in the inhibition zone diameters (IZDs, mm) caused by ciprofloxacin 
(CIP) or erythromycin (ERY) when a plant extract is present in the Mueller-Hinton agar medium. The 
methanolic extracts of C. striatus leaves, flowers and twigs were applied at 0.5 mg/mL. Inhibition zones obtained 
with the combinations (IZDc) over antibiotic-single activity (IZDa) are given and the combinations are classified 
as: (—) indifferent (IZDc – IZDa < 4 mm); (A) additive (4 ≤ IZDc – IZDa < 6 mm); and (P) potentiation (IZDc 
– IZDa ≥ 6 mm)20, 35, 36. Data are means and SD from at least three independent experiments. n.p. not performed.
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ciprofloxacin and erythromycin showed that the phenolic ingredients correlated well with the activity, which 
was confirmed by a permutation test. An S-plot was used to identify the metabolites that contributed to the 
activity. The signals in the range of δ 7.9–8.2, e.g. H-2 of isoflavonoids or H-2′ and H-6′ of flavonoids with a 
4′-monohydroxy group in the B-ring, were found to strongly correlate with the potentiating activity. To con-
firm the chemical structures associated with this activity, the C. striatus leaf methanolic extracts were separated 
using column chromatography with silica gel and then with Sephadex LH-20 yielding two fractions, B5 and 
B6, that exhibited distinct activities. The B5 fraction potentiated the activity of ciprofloxacin and erythromycin 
(similarly to C. striatus extract) and B6 showed antibacterial activity against S. aureus CECT 976. The B6 frac-
tion was identified as luteolin. Semi-preparative RP-HPLC of the B5 fraction enabled the separation of several 
compounds that were identified by 1H-NMR as apigenin, chrysin, daidzein, genistein, 2′-hydroxygenistein and 
3′-hydroxydaidzein. All compounds were identified using the in-house library of NMR data of common metab-
olites. When necessary, 2D-NMR techniques were used to confirm the identification (J-resolved, 1H-1H COSY, 
1H-13C HMBC and 1H-13C HSQC) (Table 3).
Antibacterial evaluation of the single compounds isolated from C. striatus leaves. The MICs of 
luteolin, apigenin, chrysin, genistein and daidzein against S. aureus strains were determined (Table 4). Luteolin 
was the only compound that showed antibacterial activity against S. aureus strains with a very mild MIC of 
Figure 1. Potentiating effects of ciprofloxacin and erythromycin obtained when combined with the different 
extracts of Cytisus striatus against Staphylococcus aureus CECT 976. The activity is expressed as the increase in 
the inhibition zone diameter (IZD, mm) caused by ciprofloxacin (a) and erythromycin (b) in the presence of 
the extracts of C. striatus dissolved in Mueller-Hinton agar medium. Bars represent means and SD from at least 
three independent experiments. The sample parameters (x,y) are shown in Supplementary Table 2.
Chemical formula 1H-NMR (CD3OD-d4; δ (ppm))
Apigenin C15H9O5
6.19 (H6, d, J = 1.9), 6.43 (H8, d, J = 1.9), 6.57 (H3, s), 6.92 
(H3′/H5′, d, J = 8.8), 7.84 (H2′/H6′, d, J = 8.8)
Chrysin C15H10O4
6.18 (H6, d, J = 1.9), 6.42 (H8, d, J = 1.9), 6.70 (H3, s), 7.56 
(H3′/H4′/H5′, m); 7.97 (H2′/H6′, d, J = 7.8)
Luteolin C15H9O6
6.19 (H6, d, J = 1.9), 6.42 (H8, d, J = 1.9), 6.53 (H3, s), 6.89 
(H5′, d, J = 8.4), 7.37 (H6′, dd, J = 8.4, 1.9), 7.37 (H2′, d, 
J = 1.9)
Daidzein C15H10O4
6.83 (H3′/H5′, d, J = 8.4), 6.84 (H8, d, J = 1.8), 6.92 (H6, dd, 
J = 9.0, 2.4), 7.36 (H2′/H6′, d, J = 8.4), 8.04 (H5, d, J = 8.4), 
8.12 (H2, s)
3′-Hydroxydaidzein C15H9O5
6.79 (H8, d, J = 1.8), 6.82 (H5′/H6′, m), 6.90 (H6, dd, J = 9.0, 
2.4),7.00 (H2′, d, J = 1.8), 8.02 (H5, d, J = 8.4), 8.08 (H2, s),
Genistein C15H9O5
6.20 (H6, d, J = 2.1), 6.32 (H8, d, J = 2.1), 6.84 (H3′/H5′, d, 
J = 8.4), 7.36 (H2′/H6′, d, J = 8.4), 8.04 (H2, s)
2′-Hydroxygenistein C15H10O6
6.15 (H6, d, J = 1.8), 6.26 (H8, d, J = 1.8), 6.37 (H5′, dd, J = 7.8, 
2.4), 6.39 (3′H, d, J = 1.8), 7.03 (H6′, d, J = 8.4), 7.95 (H2, s)
Table 3. Main metabolites detected in active fraction of Cytisus striatus leaves. 1H-NMR data are measured in 
ppm and coupling constants (J) in Hertz.
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between 30 and 120 µg/mL. The potentiation effect of the five isolated compounds on the activity of ciprofloxacin 
and erythromycin was tested using the checkerboard assay, and fractional inhibitory concentration index (FICI) 
values were calculated. The minimal concentration of compounds that exhibited antibiotic potentiation is shown 
for each strain. Synergy (for luteolin) or potentiation (for the nonantibacterial phytochemicals) was considered to 
be present for values of FICI ≤ 0.5. No synergistic effects were obtained with luteolin when combined with cipro-
floxacin or erythromycin (FICI > 0.5). The MIC of ciprofloxacin against RWW337 and M116 was reduced 4- and 
8-fold by apigenin (15–60 µg/mL) and its isoflavone analogue genistein (30–60 µg/mL), respectively. Genistein 
also reduced the MIC of ciprofloxacin against SA1199B 8-fold (reversing the resistance of this strain), but not 
apigenin. Daidzein (60 µg/mL) only potentiated ciprofloxacin against SA1199B (4-fold reduction). Genistein pro-
duced a 4-fold reduction of the MIC of erythromycin against RWW337, M116 and RWW50 MRSA strains. No 
potentiating effect was obtained with chrysin. No potentiation effect was observed with any of the compounds 
against the susceptible strains CECT 976, M82 and RN6390, except for genistein against CECT 976 (4-fold reduc-
tion of the MIC of ciprofloxacin and erythromycin).
Further tests are needed to determine whether the activity of the main antibacterial compound produced by 
the plant, luteolin, against S. aureus strains could also be increased in the presence of other metabolites. However, 
Figure 2. Orthogonal partial least squares modeling applied to 1H-NMR data and potentiating activity of 
Cytisus striatus samples (Fig. 2). OPLS score- and S-plots obtained from the potentiating activity (1: indifferent 
, 2: additive  and 3: potentiation effect ) and 1H-NMR data in the range of the region between δ 6.00 and 
8.60 of the different classes of potentiating activity of extracts of C. striatus on ciprofloxacin (a) and 
erythromycin (b). The sample preparation and extraction conditions were performed as shown in 
Supplementary Table 2.
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detecting the high number of possible dual and multiple interactions of the compounds as well as their optimal 
doses is quite challenging. To assess and predict real interactions of the compounds, it would be valuable to test 
the effects of such combinations on plant pathogens. This would allow a better insight into the defense system of 
this plant.
Structure activity relationship of isoflavonoids as antibiotic potentiators. To analyze the 
structure-activity relationship (SAR), 22 different isoflavonoids (Table 5) were analyzed for their antibacterial 
and antibiotic-potentiating properties. Table 6 shows the MICs obtained for the active isoflavonoids alone and 
combined with ciprofloxacin and erythromycin. Only three of these isoflavonoids showed antibacterial activ-
ity below 120 µg/mL: neobavaisoflavone, corylifol A and orobol. Synergy was observed with neobavaisoflavone 
combined with ciprofloxacin against SA1199B (FICI of 0.5) and corylifol A combined with both ciprofloxacin 
and erythromycin against RWW337 (FICIs of 0.38). Biochanin A (15–60 µg/mL) and tectorigenin (60–120 µg/
mL) showed a similar activity to genistein (30–60 µg/mL) when combined with ciprofloxacin and erythromycin 
against all cell lines except for the susceptible strains CECT 976, M82 and RN6390, for which no activity was 
found. Additionally, calycosin, irisflorentin, irigenin and daidzein (60 µg/mL) were also able to reduce the MIC of 
ciprofloxacin 4-fold against the NorA overexpressing strain SA1199B.
CIP ERY
Lut Apig Chry Gen Daid Lut Apig Chry Gen Daid
M116
MICa 30 >120 >120 >120 >120 30 >120 >120 >120 >120
MICb — 30 — 60 15 3.5 30 — 30 —
R — 4 — 4 2 2 4 — 4 —
FICI I ≤0.38 (P) I ≤0.50 (P) >0.5 (I) 0.63 (I) ≤0.38 (P) I ≤0.38 (P) I
RWW337
MICa 30 >120 >120 >120 >120 30 >120 >120 >120 >120
MICb — 60 — 60 — — 30 — 60 —
R — 8 — 8 — — ≥2 — ≥4 —
FICI I ≤0.38 (P) I ≤0.38 (P) I I* (*) I* ≤0.50 (P)* I*
RWW50
MICa 60 >120 >120 >120 >120 30 >120 >120 >120 >120
MICb — 15 — 30 — — — — 60 —
R — 2 — 2 — — — — 4 —
FICI I >0.5 (I) I >0.5 (I) I I I I ≤0.50 (P) I
M82
MICa 120 >120 >120 >120 >120 60 >120 >120 >120 >120
MICb 60 30 — 30 — 60 — — 30 —
R 4 2 — 2 — 4 — — 2 —
FICI 0.75 (I) >0.5 (I) I >0.5 (I) I 0.75 (I) I I >0.5 (I) I
RN6390
MICa 120 >120 >120 >120 >120 120 >120 >120 >120 >120
MICb — — — — — — — — — —
R — — — — — — — — — —
FICI I I I I I I I I I I
CECT 976
MICa 120 >120 >120 >120 >120 120 >120 >120 >120 >120
MICb — — — 30 30 — — — 30 —
R — — — 4 2 — — — 4 —
FICI I I I ≤0.38 (P) >0.5 (I) I I I ≤0.38 (P) I
SA1199B
MICa 120 >120 >120 >120 >120 n.p.
MICb — 10 — 60 60
R — 2 — 8 4
FICI I >0.5 (I) I ≤0.38 (P) ≤0.25 (P)
Table 4. Antibiotic-potentiating activity of the isolated compounds. Minimal inhibitory concentrations 
(MICs, µg/mL) of the compound isolated from Cytisus striatus against clinical Staphylococcus aureus, RN6390 
and SA1199B when applied alone (MICa) and in combination (MICb) with ciprofloxacin or erythromycin. 
The MICs of antibiotics are shown in Table 1. Fold reductions of antibiotic MICs in the presence of each 
phytochemical are also represented (R) as well as Fractional Inhibitory Concentration Index (FICI) values. 
When FICI ≤ 0.5 (in bold), if the phytochemical has a determinable MIC value itself, the effect is considered as 
synergy (S); if the phytochemical has no detectable MIC, the effect is called potentiation (P). If FICI > 0.5, the 
interaction is considered indifferent (I). Erythromycin was not tested against SA1199B. The values presented 
are the averages of at least three independent assays. = no decrease or increase in the MIC was observed; n.p. 
not performed; *no MIC was detected for erythromycin alone against RWW337, but when combined with 
apigenin and genistein, MIC for erythromycin was found to be at least ½ (not conclusive) and ¼ of the maximal 
concentration tested, respectively. FICI = FIC(A) + FIC(B), with FIC(A) being the ratio between the MIC of 
drug A in combination and the MIC of drug A alone and FIC(B) the ratio of the MIC of drug B in combination 
and the MIC of drug B alone.
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Effect of isoflavonoids on ethidium bromide (EtBr) accumulation. Resistance against antibiotics 
in S. aureus is, among others, related to MDR efflux pumps such as NorA (MFS family, for which several fluo-
roquinolones, monocationic dyes and disinfectants are substrates), which have been studied extensively. The 
potential of isoflavonoids to inhibit efflux pumps was assessed fluorometrically with an efflux accumulation assay 
of EtBr at ½ MIC to avoid compromising the cellular viability (MIC determination is shown in Supplementary 
Experiment 1). It has been observed that the accumulation of EtBr increased in bacterial cells in the presence of 
an efflux pump inhibitor (EPI), which inhibits the EtBr efflux activity of Gram-positive bacteria38, 39.
The real-time setup and sensitivity of the fluorometric method allowed observation of the overtime accumula-
tion of EtBr in S. aureus strains (Fig. 3a). As expected, EtBr accumulation was higher in susceptible strains, which 
present only a low basal expression of NorA and other efflux pumps. In Fig. 3(b–c), the effect of phytochemicals 
(at ½ MIC) on EtBr accumulation in the NorA overexpressing strain S. aureus SA1199B was analyzed. Reserpine 
(20 µg/mL), a recognized EPI, was used as a positive control. At a concentration of 60 µg/mL, all isoflavonoids 
were able to increase the accumulation of EtBr, except for orobol, which was already active at 30 µg/mL (data not 
shown for the other concentrations). As can be seen in Fig. 3b, isoflavonoids increased the accumulation of EtBr 
in SA1199B until approximately 40 min, after which the signal levels either stabilized or were slightly reduced 
again. Genistein, tectorigenin and orobol, and to a lesser degree apigenin, showed a different pattern (Fig. 3c), 
producing a significant increase in the accumulation of EtBr in the first 20–30 min (P < 0.05) after which values 
reverted to levels that were similar to (for genistein, P > 0.05) or lower than (for orobol and tectorigenin, P < 0.05) 
the control. Chrysin (found in C. striatus) had no effect on EtBr accumulation in SA1199B (Fig. 3d, P < 0.05). The 
positive effect of the aforementioned isoflavonoids on the accumulation of EtBr in SA1199B cells was also shown 
and confirmed by flow cytometry (Supplementary Experiment 2, Supplementary Fig. 3).
The activity of the isoflavonoids was also tested for strains M116, RWW337 and RWW50. Relative fluores-
cence (RF) values were calculated using the maximum fluorescence intensity (MFI) of each assay (Table 7). 
Independently of the differences in EtBr accumulation between the different MRSA strains, almost all the iso-
flavonoids increased the accumulation of EtBr in one or several strains, which indicates that they may target 
different proteins. Reserpine showed high values of RF for all strains. Among the isoflavonoids, biochanin A and 
tectorigenin caused the highest EtBr accumulation in MRSA strains. Calycosin and irigenin also showed high RF 
values (P < 0.05) for all MRSA strains, followed by genistein.
Discussion
It is known that plants can produce inhibitors as a protection against multidrug-resistant pathogens, thereby 
ensuring the efficient delivery of antimicrobial compounds. A good example of this is provided by Tegos 
et al.5, who found that Berberis plants, which produce a putative antimicrobial, berberine, also produce 
5-methoxyhydnocarpin D (5-MHC-D) and pheophorbide A, which are MDR inhibitors and thus increase the 
accumulation of berberine in S. aureus. The role of phytochemistry in the search for S. aureus NorA inhibitors is 
significant, having led to the discovery of several chemically diverse plant-derived EPIs, including flavones, isofla-
vones, acylated glycosides, porphyrin phaeophorbide A and kaempferol rhamnoside40, among others8.
As a bioassay-guided fractionation does not generally detect synergistic and potentiating activities due to the 
risk that interacting molecules end up in different fractions, we used metabolomics as an alternative strategy. 
Successful implementation of a metabolomics approach requires the collection of many samples with different 
levels of the different plant metabolites to be able to reveal signals or peaks related to activity. These could be sam-
ples of different plants, or alternately, different extracts from the same plant and/or their fractions. An example on 
the use of fractions has been reported by Yuliana et al.41. In the present study, different extracts of the plant were 
obtained by mixing the different plant parts in different ratios and extracting them under different conditions. 
Multivariate data analysis of the NMR spectra and the results of the bioassays enabled the identification of signals 
that were correlated to high activity (Fig. 2). NMR-based metabolomics-guided fractionation was used to isolate 
the active compounds, which were identified as apigenin, chrysin, daidzein, genistein, 2′-hydroxygenistein and 
3′-hydroxydaidzein. Apigenin showed no activity with concentrations below 120 µg/mL, in agreement with Basile 
et al.42, but not Sato et al.43. Similarly, Albert Dhayakaran et al.44 reported that MRSA strains were not inhibited 
by soy isoflavones, including genistein and daidzein (up to 100 μg/mL), and Morán et al.45 found no MIC for 
genistein up to 2 mg/mL against S. aureus CECT 59. Moreover, one antibacterial compound was identified in 
the C. striatus leaf extract – luteolin – with MICs of between 30 and 120 μg/mL against various S. aureus strains. 
Surprisingly, luteolin had lower MICs for RWW337 and M116-MRSA strains than for antibiotic-susceptible 
strains. Sato et al.43 also reported the antibacterial activity of luteolin with MICs of between 62.5 and 125 μg/ml 
against MRSA and MSSA strains. Among the isolated phenolics, apigenin and genistein clearly showed potenti-
ation of the antibiotics against RWW337, M116 and RWW50 strains (Table 4). Both isoflavones, genistein and 
daidzein, showed ciprofloxacin potentiating activity against the resistant line SA1199B (8- and 4-fold increase, 
respectively). Similarly, genistein has been reported to reduce the MIC of norfloxacin against SA1199B four-fold 
and to have a moderate MDR efflux pump inhibitory effect29. Additionally, genistein showed antibiotic potenti-
ation on the CECT 976 strain but neither genistein nor other phenolics showed the same result on the other sus-
ceptible strains M82 and RN6390. It is known that the results of antibacterial activity of phenolic compounds can 
be inconsistent, as reported by Cushnie and Lamb14, probably owing to variations in their susceptibility testing 
and differences in genetic determinants of the strains.
Isoflavones are thought to play a role in plant–microbial interactions as part of the defensive arsenal of the host 
plant, but neither this26 nor the exact relationship between chemical structure and activity is fully understood24, 27, 46. 
To further explore the possible synergistic activity, 22 isoflavonoids were tested for their antibiotic-potentiating 
effect on a number of resistant and susceptible S. aureus strains (Table 6).
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Only three compounds revealed antimicrobial activity against all S. aureus strains: neobavaisoflavone (MIC of 
20 µg/mL), corylifol A (MICs between 0.06 and 2.5 µg/mL), both of which have a lipophilic prenyl group attached 
to the B-ring, and orobol (MICs between 60 and 120 µg/mL). Besides genistein, biochanin A (a structurally simi-
lar isoflavonoid) and tectorigenin could potentiate ciprofloxacin and erythromycin (2- to 8-fold MIC reduction) 
against MRSA strains. A range of MIC values of 64–512 µg/mL against 12 S. aureus strains has been reported for 
biochanin A47. This compound also showed synergy with ciprofloxacin47. A MIC of 125 μg/mL against MRSA 
strains has been reported for tectorigenin48.
In our study, seven of the tested nonantimicrobial active isoflavonoids were able to potentiate ciprofloxacin 
activity (with 4- to 8-fold reductions of the MIC value) against the resistant SA1199B. In decreasing order of 
Flavonoid structure Isoflavonoid structure
Compounds:
Substituents at carbon position:
5 6 7 8 2′ 3′ 4′ 5′
Flavonoids
  Apigenin* OH — OH — — — OH —
  Chrysin* OH — OH — — — — —
  Luteolin* OH — OH — — OH OH —
Isoflavonoids
  Daidzein* — — OH — — — OH —
  3′-Hydroxydaidzein* — — OH — — OH OH —
  Daidzin — — O—glc — — — OH —
  Corylifol A** — — OH — — — OH R1
  Neobavaisoflavone*** — — OH — — R2 OH —
  Genistein* OH — OH — — — OH —
  2′-Hydroxygenistein* OH OH — OH — OH —
  Genistin OH — O—glc — — — OH —
  Orobol OH OH OH OH
  Calycosin — — OH — — OH OCH3 —
  Calycosin-7-O-β-D-glucoside — — O—glc — — OH OCH3 —
  Formononetin — — OH — — — OCH3 —
  Ononin — — O-glc — — — OCH3 —
  Biochanin A OH — OH — — — OCH3 —
  Tectorigenin OH OCH3 OH — — — OH —
  Tectoridin OH OCH3 O-glc — — — OH —
  Glycitein — OCH3 OH — — — OH —
  Glycitin — OCH3 O-glc — — — OH —
  Irigenin OH OCH3 OH — — OH OCH3 OCH3
  Iridin OH OCH3 O-glc — — OH OCH3 OCH3
  Puerarin — — OH glc — — OH —
  3′-Hydroxypuerarin — — OH glc — OH OH —
  3′-Methoxypuerarin — — OH glc — OCH3 OH —
  Irisflorentin**** OCH3 R3 R3 — OCH3 OCH3 OCH3 —
Table 5. Structures of flavonoids and isoflavonoids found and/or tested in this study. Compounds with (*) were 
isolated from C. striatus leaves.
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CIP
Neob CorA Orob Gen Tect BiochA Calyc Irig Gly Daid Irisfl
M116
MICa 20 2.5 120 >120 >120 >120 >120 >120 >120 >120 >120
MICb 5 — 60 60 60 30 — — — 15 —
R 2 — 8 4 2 4 — — — 2 —
FICI 0.75 (I) I 0.63 (I) ≤0.50 (P) >0.5 (I) ≤0.38 (P) I I I >0.5 (I) I
RWW337
MICa 20 20 120 >120 >120 >120 >120 >120 >120 >120 >120
MICb 5 5 60 60 60 30 30 60 — — —
R 2 8 4 8 4 4 2 2 — — —
FICI 0.75 (I) 0.38 (S) 0.63 (I) ≤0.38 (P) ≤0.50 (P) ≤0.38 (P) >0.5 (I) >0.5 (I) I I I
RWW50
MICa 20 2.5 120 >120 >120 >120 >120 >120 >120 >120 >120
MICb 10 — — 30 60 15 30 30 — — —
R 4 — — 2 2 2 2 2 — — —
FICI 0.75 (I) I I >0.5 (I) >0.5 (I) >0.5 (I) >0.5 (I) >0.5 (I) I I I
M82
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120
MICb 10 1.25 — 30 30 30 — 60 — — —
R 4 2 — 2 2 2 — 2 — — —
FICI 0.75 (I) 1 (I) I >0.5 (I) >0.5 (I) >0.5 (I) I I I I I
RN6390
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120
MICb 10 — — — — — — — - — —
R 4 — — — — — — — — — —
FICI 0.75 (I) I I I I I I I I I I
CECT 976
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120
MICb 10 — — 30 60 60 60 60 — 30 60
R 2 — — 4 2 2 2 2 — 2 2
FICI 1.0 (I) I I ≤0.38 (P) >0.5 (I) >0.5 (I) >0.5 (I) >0.5 (I) I >0.5 (I) >0.5 (I)
SA1199B
MICa 20 0.06 60 >120 >120 >120 >120 >120 >120 >120 >120
MICb 5 — 15 60 60 30 60 60 60 60 60
R 4 — 2 8 4 8 4 4 2 4 4
FICI 0.50 (S) I >0.5 (I) ≤0.38 (P) ≤0.50 (P) ≤0.38 (P) ≤0.50 (P) ≤0.50 (P) >0.5 (I) ≤0.25 (P) ≤0.50 (P)
ERY
M116
MICa 20 2.5 120 >120 >120 >120 >120 >120 >120 >120 >120
MICb — 1.25 — 30 60 15 30 60 — — —
R — 2 — 4 4 4 2 2 — — —
FICI I 1 (I) I ≤0.38 (P) ≤0.38 (P) ≤0.28 (P) >0.5 (I) >0.5 (I) I I I
RWW337
MICa 20 20 120 240 >240 >240 >240 >240 >120 >120 >120
MICb — 5 60 60 120 60 — — — — —
R — ≥8 ≥4 ≥4 ≥2 ≥4 — — — — —
FICI I* ≤0.38 (S)* >0.50 (I)* ≤0.50 (P)* (*) ≤0.50 (P)* I* I* I I I
RWW50
MICa 20 2.5 120 >120 >120 >120 >120 >120 >120 >120 >120
MICb 10 — — 60 60 60 30 60 — — —
R 8 — — 4 4 4 2 2 — — —
FICI 0.63 (I) I* I* ≤0.50 (P) ≤0.50 (P) ≤0.50 (P) >0.5 (I) >0.5 (I) I I I
M82
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120
MICb 5 1.25 — 30 60 30 120 60 — — —
R 2 2 — 2 2 2 2 2 — — —
FICI 0.75 (I) 1 (I) I ≥0.56 (I) ≥0.63 (I) ≥0.56 (I) >0.5 (I) >0.5 (I) I I I
RN6390
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120
MICb 10 — — — — — — — — — —
R 4 — — — — — — — — — —
FICI 0.75 (I) I I I I I I I I I I
CECT 976
MICa 20 2.5 60 >120 >120 >120 >120 >120 >120 >120 >120
MICb — 1.25 — 30 60 — 60 60 — — —
R — 2 — 4 2 — 2 2 — — —
FICI I 1 (I) I ≤0.38 (P) >0.5 (I) I >0.5 (I) >0.5 (I) I I I
Table 6. Antibiotic-potentiating active isoflavonoids. Minimal inhibitory concentrations (MICs, µg/mL) of the 
isoflavonoids against clinical S. aureus, RN6390 and SA1199B when applied alone (MICa) and in combination 
(MICb) with ciprofloxacin or erythromycin. The MICs of antibiotics are shown in Table 1. Fold reductions of 
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activity, these were genistein, biochanin A, tectorigenin, daidzein, calycosin, irigenin and irisflorentin (Table 6). 
Genistein and biochanin A were the most active of all the tested isoflavonoids, potentiating both ciprofloxa-
cin and erythromycin against resistant S. aureus strains. A comparison of their structures suggests that the two 
hydroxyl groups in a meta position in the A-ring in these compounds are a key feature of this antibiotic potenti-
ation. Orobol, which also has the same A-ring substitution but two ortho-hydroxyl groups in the B-ring, shows 
antibacterial activity. Tectorigenin, which differs from genistein by one additional methoxy group in C-6, also had 
significant potentiating activity. Daidzein, which lacks the 5-hydroxy group but is otherwise identical to genistein, 
is less active. It seems that synergistic properties parallel the estrogenic activity49. Furthermore, all compounds 
in which the C-7 hydroxyl group was glycosylated were inactive. The results reported by Hummelova et al.25 
agree partially with our observations, since the isoflavonoids with the strongest S. aureus inhibitory effect were 
ortho-dihydroxyisoflavones. Other studies showed that 5,7-dihydroxylation of the flavonoid A-ring was impor-
tant for anti-MRSA activity25, 50, 51 and monomethoxy B-ring derivatives were generally found to be more active 
(antibiotic synergy) than the disubstituted B-ring derivatives29.
The next question to answer was the possible mode of action of the synergistic activity. The uptake and efflux 
of the antibiotics are decisive for this activity. A higher accumulation of an antibiotic can be related to one of the 
following processes: the increase of nonselective diffusion, the presence of more or less selective transporters for 
uptake or inhibitors of the efflux transporters. The mechanism behind transport inhibition is not well understood. 
There is strong evidence that some EPIs, such as reserpine, can bind to several transporters, probably due to the 
low substrate specificity of these systems52. Nevertheless, it seems that the most active agents belong to the fami-
lies of compounds possessing a conjugated system40. Ethidium bromide is a substrate for many efflux systems in 
various microorganisms, including S. aureus12, and has been shown to be a particularly suitable probe for efflux 
studies, since it emits weak fluorescence in aqueous solution (external to the cell) and becomes strongly fluores-
cent when it binds to cellular components53. To measure the effect on the uptake and efflux, the accumulation of 
the highly fluorescent EtBr in the bacteria was measured in the presence of the isoflavonoids. Some isoflavonoids 
seemed to induce a fast EtBr accumulation, but over time the levels in the cell reverted to those of the controls, 
meaning that an equilibrium was reached after a certain time. The seven isoflavonoids that potentiated the activ-
ity of ciprofloxacin against SA1199B were those that most increased the accumulation of EtBr. No effect was 
observed in SA1199B when apigenin and chrysin (found in C. striatus) were combined with ciprofloxacin.
When studying efflux activity in MRSA clinical isolates instead of well-defined collection strains, the myriad 
of bacterial responses can complicate the clear interpretation of data. Bacterial response to ciprofloxacin is medi-
ated, in most cases, not by one single efflux pump but by several (such as SdrM, MdeA, MepA, NorA, NorB or 
NorC), thereby hampering the perception of the role played by each individual pump in the overall efflux activity/
resistance phenotype54. The same substrate can promote the expression of different efflux pump genes depending 
on its concentration and/or time of exposure. Also, isolates belonging to the same clonal type can have different 
levels of efflux activity and respond to the same agent through the activation of different efflux pumps55. The 
RWW337 strain showed a poor accumulation of EtBr, like SA1199B, followed by M116 strain, suggesting that, 
in contrast to the other strains, there is an overexpression of NorA or other related MDR efflux pumps in these 
strains. Nevertheless, biochanin A, tectorigenin and genistein improved EtBr accumulation as compared to the 
control in all MRSA strains (Table 7). Calycosin and irigenin had lower RFs, but still improved EtBr accumula-
tion as compared to the control in all MRSA strains. These results suggested that an inhibition of efflux pumps, 
known to be involved in resistance mechanisms, or an effect on membrane permeability could contribute to the 
potentiation effect of the isoflavonoids. Cell membrane damage has been reported in connection with the isofla-
vonoids48, 56.
This study aimed to identify active antibiotic adjuvants from plants using a metabolomics approach. In previ-
ous studies, the plant Cytisus striatus showed interesting antimicrobial activity. By combining the metabolomics 
data with the activity of a number of different extracts prepared from the same plant, and by applying multivariate 
data analysis, it was possible to identify the signals that correlate with a potentiating effect on two antibiotics. 
These signals belonged to two types of plant secondary metabolites, flavonoids and isoflavonoids, the activities 
of which were partly known. The results prove that NMR-based metabolomics is a powerful tool for identifying 
synergistic activities, enabling the identification of the involved metabolites.
To investigate whether the activity observed with these particular compounds could be extended to other 
isoflavonoids, and if so, if there were some structural features related to the activity, 22 structurally differ-
ent isoflavonoids were tested for their potentiating activity of ciprofloxacin and inhibition of the NorA efflux 
pump. This showed that the antimicrobial and antibiotic-potentiation properties of isoflavonoids are highly 
structure-dependent. All results are clearly promising and open the door to further research questions such as 
antibiotic MICs in the presence of each isoflavonoid are also represented (R) as well as Fractional Inhibitory 
Concentration Index (FICI) values. When FICI ≤ 0.5 (in bold), if the isoflavonoid has a determinable MIC 
value, the effect is considered as synergy (S); if the isoflavonoid has no detectable MIC, the effect is called 
potentiation (P). If FICI > 0.5, the interaction is considered indifferent (I). Nonactive isoflavonoids are not 
included. ERY was not tested against SA1199B. The values presented are the averages of three independent 
assays. = no decrease or increase in the MIC was observed; n.p. not performed; *no MIC was detected for 
erythromycin alone against RWW337, but when combined with genistein and biochanin A, erythromycin 
MIC was found to be at least ¼ of the maximal concentration tested, and at least ½ for tectorigenin. 
FICI = FIC(A) + FIC(B), with FIC(A) being the ratio between the MIC of drug A in combination and the MIC 
of drug A alone and FIC(B) the ratio of the MIC of drug B in combination and the MIC of drug B alone.
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Figure 3. Effect of isoflavonoids on EtBr accumulation in Staphylococcus aureus SA1199B. In (a), fluorescence 
as a measure of EtBr accumulation is shown for all Staphylococcus aureus strains for 60 min at 37 °C; EtBr 
was applied at ½ MIC and fluorescence measurement obtained by fluorometric method; in (b), only the 
isoflavonoids (60 µg/mL) increasing the accumulation of EtBr in SA1199B cultures over control over time 
(P < 0.05) are represented; the changes in the accumulation of EtBr in SA1199B are also shown for genistein, 
tectorigenin (both at 60 µg/mL) and orobol (30 µg/mL) (c) and for the flavonoids apigenin and chrysin (d). 
Reserpine at 20 µg/mL was used as a positive control as efflux pump inhibitor (EPI). Mean values of least three 
independent experiments are shown.
SA1199B RWW337 M116 RWW50
Reserpine 0.53 ± 0.19 0.25 ± 0.10 0.62 ± 0.14 0.75 ± 0.21
Daidzein 0.33 ± 0.10 0.05 ± 0.02 0.05 ± 0.09 −0.08 ± 0.06
Genistein 0.67 ± 0.19 0.20 ± 0.10 0.13 ± 0.11 0.12 ± 0.07
Tectorigenin 0.81 ± 0.12 0.19 ± 0.09 0.42 ± 0.07 0.47 ± 0.04
Glycitein 0.31 ± 0.10 0.06 ± 0.05 −0.02 ± 0.00 0.07 ± 0.05
Biochanin A 0.44 ± 0.05 0.63 ± 0.15 0.33 ± 0.08 0.47 ± 0.08
Calycosin 0.63 ± 0.11 0.19 ± 0.13 0.22 ± 0.03 0.34 ± 0.13
Irisflorentin 0.23 ± 0.03 0.05 ± 0.11 0.30 ± 0.05 0.02 ± 0.08
Irigenin 0.48 ± 0.15 0.15 ± 0.10 0.28 ± 0.04 0.34 ± 0.06
Orobol 0.76 ± 0.18 0.07 ± 0.04 0.08 ± 0.14 −0.13 ± 0.01
Apigenin 0.22 ± 0.05 0.01 ± 0.05 0.04 ± 0.03 0.05 ± 0.05
Chrysin 0.09 ± 0.07 −0.03 ± 0.02 −0.03 ± 0.10 0.01 ± 0.01
Table 7. Effect of isoflavonoids on the accumulation of ethidium bromide by fluorometry. Relative fluorescence 
(RF) values were calculated for all isoflavonoids by fluorometric method in SA1199B and three MRSA strains. 
Reserpine was used as positive efflux pump inhibitor control. The flavonoids apigenin and chrysin found in 
Cytisus striatus leaves were included in the assay. The RF values are the averages and standard deviations of at 
least three independent assays.
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the structure-activity relationship of isoflavonoids for potentiating the activity of antibiotics, or more specifically 
in inhibiting efflux pumps, also possibly in other organisms. This might be interesting also for other potentiating 
effects on other pharmacological activities. Furthermore, given that the inhibition of NorA did not explain the 
potentiation observed for erythromycin, further work should be done to analyze the possible interference with 
other cellular efflux pumps. The concept of restoring and enhancing the therapeutic value of antimicrobials by 
employing EPIs is a formidable challenge. The development of combinations of fluoroquinolone antibiotics with 
a transporter inhibitor appears to be a feasible alternative to the discovery of “rare” antibiotics that are poorly 
recognized by multidrug transporters. Revealing the mechanisms plants may use to resist microbial infections, 
including molecules that affect the efflux of antimicrobials, may be promising for the discovery of compounds 
that potentiate and thus “recycle” antimicrobial drugs.
Methods
Plant material. Cytisus striatus (Hill) Rothm. was collected from Trás-os-Montes and Beira Transmontana 
(Portugal) in April and May of 2013 and identified by the botanical garden in Vila Real (Portugal). The leaves, 
flowers and twigs were harvested, separated, immediately frozen in liquid N2 and freeze-dried in order to avoid 
unwanted enzymatic reactions and stored at −20 °C until analysis.
Preparation of plant samples and extracts. To study the activity of C. striatus leaves, flowers and twigs, 
5 g of each of these plant materials were extracted with 50 mL of MeOH at 30 °C, while stirring at 150 rpm for 
60 min. After filtration, the extracts were dried using a rotary evaporator and redissolved in 10 mL of methanol. 
This extract was partitioned with n-hexane (3 × 10 mL) to eliminate lipophilic compounds. The remaining meth-
anolic phase was evaporated using a rotary evaporator and redissolved in H2O/MeOH (95:5). The resulting solu-
tion was extracted with 3 × 10 mL portions of ethyl acetate and the extracts were combined and evaporated with 
a rotary evaporator (EtOAc fraction). These extracts were analyzed by 1H-NMR and tested for both antibacterial 
and antibiotic-potentiating activities. The hexane and remnant H2O/MeOH fractions were also tested in order to 
ensure the absence of compounds of interest in these extracts (data not shown).
A multi-extraction strategy was performed for multivariate data analysis. To generate metabolic vari-
ation, leaves or flowers and twigs of C. striatus were mixed in different proportions (0, 25, 50, 70, 85, 100% 
(w (leaf or flower)/w (twig)). Approximately 1 g of each of these samples was extracted using different conditions of 
pressure and temperature with an E-916 speed extractor (Büchi, Flawil, Switzerland). The tested conditions were: 
temperature 30 or 90 °C, pressure 50 or 100 bar, solvent 50, 75 or 100% aqueous MeOH. For all conditions, the 
extraction was performed using two 4-minute cycles with a flow of 3 mL of solvent/min. The samples were labeled 
using a binary numbering system (x,y), where x specifies the extraction conditions and y the sample composition 
(Supplementary Table 2). In total, 54 different samples were extracted and vacuum-dried (Syncore, Büchi).
All the samples were redissolved in 10 mL of methanol and submitted to the fractionation scheme described 
previously. The ethyl acetate fractions were taken to dryness with a rotary evaporator, analyzed by 1H-NMR and 
tested for both antibacterial and antibiotic-potentiating activities.
Bacterial strains. Seven S. aureus strains were used in this study. Further details are shown in Table 1. Prior 
to use, each strain, kept at −80 °C, was transferred onto Tryptic Soy Agar (TSA) with 5% sheep’s blood (BD, 
Breda, the Netherlands) plate, grown overnight and inoculated into MH broth at 37 °C with agitation (150 rpm). 
The antibacterial susceptibility of the strains was tested using a Vitek® II (bioMérieux); the antimicrobial suscep-
tibility test was analyzed according to the CLSI guidelines32, 57.
Antibiotics and phytochemical compounds. Ciprofloxacin and erythromycin were purchased from 
Sigma-Aldrich (St. Louis, USA) and stock solutions were prepared according to CLSI guidelines57. Three flavo-
noids, luteolin, apigenin and chrysin, and 22 isoflavonoids, biochanin A, calycosin, calycosin-7-O-β-D-glucoside, 
corylifol A, daidzein, daidzin, genistein, genistin, glycitein, glycitin, formonenetin, 3′-hydroxypuerarin, iridin, 
irigenin, irisflorentin, 3′-methoxypuerarin, neobavaisoflavone, ononin, orobol, puerarin, tectoridin and tect-
origenin, were purchased from Biopurify, Chendu, China. Stock solutions were prepared in dimethyl sulfoxide 
(DMSO; Sigma-Aldrich, St. Louis, USA). Table 5 shows the chemical structures of all the flavonoids and isofla-
vonoids used in this study. Reserpine (Sigma-Aldrich), a recognized EPI58, 59, was used as positive control in EtBr 
accumulation assays and prepared in the same way.
Antibacterial susceptibility testing. The MIC was determined using the microdilution broth method 
according to CLSI guidelines32. Bacteria (~106 CFU/mL) were inoculated into MH broth and 200 μL/well were 
distributed in 96-well microtiter plates, along with twofold dilutions of the compounds to test. The MIC was 
defined as the lowest concentration of the compound that inhibited bacterial growth after 24 h of incubation at 
37 °C. The bacterial growth was determined at 600 nm using a microplate reader (Spectramax M2e, Molecular 
Devices, Inc.). Three independent experiments were performed for each compound. The highest concentration 
of DMSO remaining after dilution (5%, v/v) caused no inhibition of bacterial growth.
Antibiotic-potentiation testing – disk diffusion test. This method is most suitable for testing plant 
extracts, as it allows a better visualization and detection of the potentiating effects. The test was performed as 
described in previous studies20, 35, 36. Dried C. striatus extracts were prepared in DMSO. Each extract was added 
to previously autoclaved and cooled MH agar in the amount calculated to obtain the required final concentra-
tion. Then, 20 mL of medium were poured into 90 mm Petri dishes. The bacterial suspensions were adjusted to 
0.5 McFarland standard and seeded over hardened MH agar Petri dishes using a sterilized cotton swab. Sterile 
blank discs (6 mm diameter; Oxoid) were placed on the agar plate seeded with the respective bacteria. A volume 
of 10 µL of each antibiotic prepared according to the CLSI guidelines (ciprofloxacin – 5 µg/disc; erythromycin 
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– 15 µg/disc)57 was added to the blank discs. Antibiotic- and DMSO-impregnated discs on simple MH agar plates 
were used as positive and negative controls, respectively. The plates were incubated at 37 °C for 24 h. After incu-
bation, each IZD was recorded and analyzed according to CLSI guidelines57. No inhibition zone was obtained 
with DMSO. All tests were performed in triplicate. The antibiotic-potentiating activity of C. striatus extracts was 
categorized, as described in previous studies20, 35, 36, into three classes according to the ratio of the increase of the 
IZD produced by the antibiotic in the presence of the plant extracts to that obtained with the antibiotic alone (on 
simple MH agar plates): 1 – indifferent (IZD combination – IZD antibiotic < 4 mm); 2 – additive (4 ≤ IZD combi-
nation – IZD antibiotic < 6 mm); and 3 – potentiation (IZD combination – IZD antibiotic ≥ 6 mm) of inhibition 
of growth of S. aureus.
Antibiotic-potentiation testing – checkerboard. The checkerboard assay was performed according 
to CLSI guidelines32 as described in previous studies20, 35, 36. The MICs of ciprofloxacin and erythromycin were 
determined in the presence of increasing amounts of the tested compounds against S. aureus strains. Twofold 
serial dilutions in MH were carried out for the antibacterial compounds, yielding final concentrations ranging 
from 2 × MIC to 1/64 × MIC. Compounds with no detectable antibacterial activity were tested at several concen-
trations between 120 and 0.06 µg/mL. Drug combinations did not exceed 5% (v/v) of the volume used in each well 
(200 µL). Growth controls consisted in 5% (v/v) DMSO solutions and negative controls were prepared by adding 
fresh MH without bacteria to each drug combination. Incubation was performed for 24 h at 37 °C and measured 
spectrophotometrically at 600 nm. All MIC determinations were repeated at least in triplicate. Synergistic inter-
actions between two drugs, one being an antibiotic (A) and the other being the adjuvant (B), were classified using 
the FIC index: FICI = FIC(A) + FIC(B), where FIC(A) is the ratio between the MIC of drug A in combination 
and the MIC of drug A alone, and FIC(B) is the ratio of the MIC of drug B in combination and the MIC of drug 
B alone60. A FICI value of ≤0.5 was interpreted as synergy. When the MIC B alone was not detected in the range 
of tested concentrations, double the highest concentration that was tested was used for FICI determination, and 
if the FICI value was ≤0.5, this interaction was assumed to be a potentiation60.
NMR analysis. Each dried sample was mixed with 500 μL of CH3OH-d4, vortexed for 10 s, sonicated for 
20 min at 42 kHz and then centrifuged at 13,000 rpm at room temperature for 5 min. The supernatant (300 μL) 
was transferred to a 3 mm micro-NMR tube and analyzed. 1H-NMR spectra were recorded at 25 °C on a 600 MHz 
Bruker DMX-600 spectrometer (Bruker, Karlsruhe, Germany) operating at a proton Larmor frequency of 
600.13 MHz. Methanol-d4 was used as the internal lock. The 1H-NMR experimental parameters were the follow-
ing: 128 scans requiring 10 min and 26 s acquisition time, 0.16 Hz/point, pulse width (PW) = 30° (11.3 μs) and 
relaxation delay (RD) = 1.5 s. FIDs were Fourier transformed with LB = 0.3 Hz. The resulting spectra were manu-
ally phased and baseline corrected, and calibrated to MeOH-d4 at 3.3 ppm, using TOPSPIN 3.2 software (Bruker 
BioSpin GmbH, Rheinstetten, Germany). 2D-NMR techniques (J-resolved, 1H-1H COSY, 1H-13C heteronuclear 
multiple-bond correlation (HMBC), and 1H-13C heteronuclear single quantum coherence (HSQC)), were per-
formed when necessary as previously described37, 61.
Isolation of the bioactive compounds. NMR-guided isolation was used to isolate the bioactive com-
pounds from C. striatus leaves for their identification. For this, 55 g of leaves were extracted with 500 mL of 
MeOH and fractionated with ethyl acetate as described before in the section “Preparation of plant samples and 
extracts”. The resulting dry ethyl acetate fraction (1.2 g) was subjected to medium-pressure liquid chromatography 
(MPLC). Samples were introduced as solids using a pre-Elut column connected just before the main separation 
column (200 × 35 mm, i.d., Sepacore® Silica 80 g, Büchi, Switzerland) and eluted using a gradient of chloroform 
(A) and methanol (B) (B:10%, 15 min; B:10–30%, 5 min; B: 30%, 20 min; B: 30–50%, 5 min; B:50%, 10 min) at a 
flow rate of 20 mL/min. The eluant was monitored at 220, 254, 280 and 365 nm. Sixty fractions were collected 
and combined into six fractions according to their TLC profile similarities. The TLC was performed on silica gel 
plates (Si60 HF254, Merk, Darmstadt, Germany) with CHCl3:MeOH:acetic acid (7.5:2.5:0.2). These six fractions 
were prepared for 1H-NMR analysis and for their antibacterial-potentiating analysis as described previously. One 
of the fractions (A3) proved to be active according to the disk diffusion method. This fraction (270 mg) was sep-
arated on a Sephadex LH-20 column with methanol at a flow of 3.5 mL/min and monitored at 220, 254, 280 and 
365 nm. Sixty subfractions were collected and combined into six fractions (B1–B6) according to their TLC profile 
similarities. These were analyzed by 1H-NMR and tested for their antibacterial-potentiating capacity. Out of all 
these subfractions (B), two (B5 and B6) showed activity. B5 proved to have an antibiotic-potentiating activity with 
both ciprofloxacin and erythromycin and B6 had antibacterial activity against S. aureus strains. The B5 fraction 
(13.5 mg) was purified by semi-preparative reverse-phase high-performance liquid chromatography (RP-HPLC) 
(Luna C18 column; 250 × 10 mm, i.d., 5 μm, Phenomex®) and eluted with a gradient of 1% aqueous acetic acid (A) 
and methanol (B) (B: 1–42%, 30 minutes; B: t 42–100%, 10 minutes; B: 100%, 2 minutes). The detector was set at 
270 nm. Six main fractions were obtained and analyzed by 1H-NMR analysis for the identification of metabolites, 
and 2D-NMR techniques were used when necessary. The B6 fraction (8.3 mg) contained only one compound that 
was identified as luteolin.
EtBr accumulation assay by the fluorometric method. EtBr accumulation by the S. aureus strains on 
a real-time basis was detected using a fluorometric method in a 96-well plate fluorometer following modified pub-
lished methods12, 62. The MIC of EtBr (prepared as a stock of 10 mg/mL) was determined for each strain according 
to CLSI guidelines as previously described. Briefly, S. aureus strains were grown in MH medium at 37 °C until 
the mid-log phase (OD600 of 0.6 to 0.7). Cultures were centrifuged at 13,000 rpm for 5 min, the supernatant was 
discarded and the pellet was washed in phosphate-buffered saline (PBS; pH 7.4). The OD600 was adjusted to 0.4 
with PBS. Aliquots of 100 µl of bacterial suspension were transferred into the wells of a 96-well plate containing 
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serial dilutions of EtBr at concentrations ranging from 80.00 to 0.06 µg/mL. In order to determine the effect of the 
isoflavonoids on the EtBr accumulation, EtBr (at ½ MIC) was applied in the absence of each isoflavonoid or with 
concentrations of 15, 30 and 60 µg/mL. Reserpine (20 μg/mL) was used as a positive control as it is a recognized 
EPI39. The negative control consisted of 1% (v/v) DMSO. Relative fluorescence was acquired every 60 s for 60 min 
at 37 °C in a Fluostar Optima (BMG Labtech, Ortenberg, Germany), using 530 nm and 590 nm as excitation 
and detection wavelengths, respectively. To be able to compare the EtBr accumulation experiments, the relative 
fluorescence (RF) was determined for each assay. The RF was calculated applying the equation RFassay = (MFIassay 
−FIcontrol)/ FIcontrol, where MFIassay was the maximum fluorescence intensity (MFI) obtained in each 60 min assay 
and FIcontrol was the corresponding fluorescence intensity (FI) obtained with the DMSO control at the same time. 
High RF values indicated that cells accumulated more EtBr under the tested conditions than the control and vice 
versa for negative values. The experiments were repeated three times, and the RF values presented are the averages 
of the three independent assays.
EtBr accumulation assay by flow cytometry. Flow cytometry facilitates the analysis of cells in sus-
pension as they pass through a beam of light at a high rate in a fluid stream. Data acquisition and analysis were 
performed using a BD Accuri™ C6 flow cytometer (Breda, the Netherlands) equipped with three fluorescence 
detectors: FL1 (515 to 565 nm), FL2 (565 to 605 nm) and FL3 (>605 nm). The maximum absorption for EtBr is 
518 nm and the maximum fluorescence emission is 605 nm. Preparation of S. aureus strains was performed as 
described in the fluorometric method and the strains were distributed in aliquots of 100 µL. The EtBr was added at 
½ MIC and the isoflavonoids were added at the best concentration as defined with the previous method. Positive 
controls were performed with 20 µg/mL of reserpine and negative controls with 1% (v/v) DMSO. Following incu-
bation at 25 °C for 60 minutes, the supernatant was removed and the pellet was resuspended in EtBr-free PBS, 
adjusting the OD600 to 0.3. Samples were taken for measuring fluorescence in the BD Accuri™ C6 flow cytometer. 
Data was collected for at least 10,000 events per sample. In this method, the final median fluorescence intensities 
were recorded and RF values were calculated as previously explained.
Data analysis and statistics. The NMR spectra were bucketed using AMIX 3.9.12 (Bruker BioSpin GmbH, 
Rheinstetten, Germany). Buckets were obtained by integrating 0.04 ppm intervals and scaling the intensity of 
individual peaks to the total intensity recorded in the region δ 0.20–10.02. The regions of δ 4.85–4.95 and δ 3.20–
3.40 were excluded from the analysis because of the residual signal of D2O and CD3OD, respectively. Orthogonal 
projection to latent structures (OPLS) based on Pareto scaling was performed with the SIMCA-P + software (v. 
12.0, Umetrics, Umeå, Sweden). The outliers were not considered. The metabolites contributing to the separation 
were analyzed using an S-plot of the OPLS modeling.
For antibacterial-potentiating and EtBr accumulation tests, means and standard deviations were calculated 
and mean comparisons were made using the Student’s t-test (two-tailed based on a confidence level <0.05).
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